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Severe sepsis or septic shock is one of the rising causes for mortality worldwide representing nearly 10% of
intensive care unit admissions. Susceptibility to sepsis is identified to be mediated by innate pattern
recognition receptors and responsive signaling pathways of the host. The c-Jun N-terminal Kinase
(JNK)-mediated signaling events play critical role in bacterial infection triggered multi-organ failure,
cardiac dysfunction and mortality. In the context of kinase specificities, an extensive library of
anthrapyrazolone analogues has been investigated for the selective inhibition of c-JNK and thereby to gain
control over the inflammation associated risks. In our comprehensive biochemical characterization, it is
observed that alkyl and halogen substitution on the periphery of anthrapyrazolone increases the binding
potency of the inhibitors specifically towards JNK. Further, it is demonstrated that hydrophobic and
hydrophilic interactions generated by these small molecules effectively block endotoxin-induced
inflammatory genes expression in in vitro and septic shock in vivo, in a mouse model, with remarkable
efficacies. Altogether, the obtained results rationalize the significance of the diversity oriented synthesis of
small molecules for selective inhibition of JNK and their potential in the treatment of severe sepsis.
S
epsis, leading to organ dysfunction and hypotension unresponsive to fluid resuscitation, presents a signifi-
cant challenge in preventive measures for mortality in hospital intensive care units (ICU). Sepsis causes
millions of deaths every year worldwide1–4. Sepsis is often characterized by deregulated expression of wide-
ranging host inflammatory genes leading to irreparable pathologies5. Integrated signaling pathways in host cells,
which in turn tightly regulate transcriptional activation of inflammatory genes, frequently mediate these cellular
events6. Owing to this sudden onset and excessive induction of inflammatory genes such as COX-2 and its
catabolic end product PGE2 in addition to TNF-a, IL-12, IL-6, etc leads to multiple organ failure including vital
organs like heart and central nervous system resulting in the death of individual7–9. It is observed that stress
activated protein kinases (SAPKs) which comprise two main subsets, c-Jun N-terminal Kinase (JNK) and p38
MAPK (Mitogen Activated Protein Kinase), execute cell-fate decisions during sepsis10. SAPK/JNK family of
kinases regulate downstream signaling events by controlled activation of c-Jun and c-Fos11,12. Phosphorylation
of c-Jun by activated JNK at ser63 or ser73 promotes its interaction with c-Fos forming a functional transcription
factor activator protein-1 (AP-1), a key regulator of pro-inflammatory genes expression (Fig. 1)13–16. AP-1 often
acts as molecular switch in deciding cell-fate decisions across many cell types17. In this perspective, design and
synthesis of highly potent target-specific inhibitors with limited or no off-target effects across cellular platforms
assumes great importance to treat several disease-associated pathologies including sepsis18.
There are three isoforms of JNK:While JNK1 and JNK2 are found in all tissues, interestingly, JNK3 is localized
to neuronal tissues, cardiac myocyte, and testes19,20. Thus, the distribution and expression patterns appear to
contribute to the regulation of wide-ranging inflammatory immune responses whichmight also include sepsis. In
this perspective, development of small molecule JNK inhibitors that are cell permeable, possessing rapid and
reversible kinetics might provide powerful leads to develop therapeutics for the treatment of inflammatory
disorders. Among the existing JNK selective inhibitors, SP600125 (anthra [1, 9] pyrazol-6 (2H)-one or 1,9-
pyrazoloanthrone, Fig. 2), an anthrapyrazolone, is often utilized as a strong inhibitor of c-Jun N-terminal kinase
catalytic activity. SP600125 inhibits JNK1, JNK2, and JNK3 with a high specificity and markedly inhibits the
activation/phosphorylation of c-Jun as well as expression of inflammatory genes21. Despite its specificity, poor
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solubility in aqueous solutions and off-target effects on other kinases
likemonopolar spindle 1 (Mps1) has opened up new challenges in it’s
utility in treating severe sepsis22–26. The crystal structure of 1,9-pyr-
azoloanthrone (anthrapyrazolone) was found to display a positional
disorder at the NH group of pyrazole ring and anthraquinone ring
(Supplementary Fig. S1a) and its relevance in sensing specific anions
has been traced to this disorder and more so to the acidity of the NH
group27. Indeed the acidity of the NH group and pyrazole moiety of
1,9-pyrazoloanthrone is effective in forming specific hydrogen bond-
ing at the ATP-biniding site of JNK. 1,9-pyrazoloanthrone forms
hydrogen bonds with the carbonyl oxygen of Glu147 and the main
chain nitrogen of Met149 in the enzyme-inhibitor complex (Protein
Data Bank Code 1PMV) as shown in Fig. S1b-d, Supplementary
Information28. As a consequence, several hydrophobic contacts with
Ile70, Ala91, Met146, Leu148, Asp150, Asn152, Val196 and Leu206
develop at the active site of JNK.
Substitution of N-alkyl groups (methyl and ethyl) on 1,9-pyrazo-
loanthrone (anthrapyrazolone) resulted in the strengthening of
hydrophobic interactions with the active site residues. However these
experiments showed reduced inhibitory activity21. In a recent study,
we have demonstrated the enhancement of hydrophobic interactions
in two specific N-alkyl derivatives of 1,9-pyrazoloanthrone (propyl
(SPP1) and butyl (SPB1)) with inhibition of c-JNK at lower concen-
tration values ,10 mM, considerably lesser than the concentrations
required to inhibit c-JNK by 1,9-pyrazoloanthrone29. It was also
shown by Brydon et al., that substitution at the 7-position of 1,9-
pyrazoloanthrone with a chlorine atom resulted in 2-fold improve-
ment of inhibition21. These observations prompted us to explore an
extensive library of 1,9-pyrazoloanthrone analogues (Fig. 2) with
potent inhibitory capacities towards inhibition of JNK. In this study,
rigorous evaluation of several anthrapyrazolone analogues has been
carried out to assess the efficacy in terms of effects on expression
profiles of inflammatory genes associated with septic shock both in
vitro (in macrophages) and in vivo in murine model of sepsis. These
analogues exhibited enhanced inhibitory activity over JNK (.10 fold
than SP600125) with high selectivity and specificities. Altogether, we
demonstrate the development and functional characterization of a
series of specific compounds, which could act both as promising tools
in elucidating the essential role of JNKs in cellular physiological
processes as well as in the development of novel therapeutics to treat
sepsis.
Results
We have prepared a series of compounds based on anthrapyrazolone
as a scaffold with different substitutions (Fig. 2) and the synthesis
scheme is shown in Fig. S2 of Supplementary Information. The ana-
Figure 1 | Endotoxin (LPS)mediated activation of JNK through Toll Like
Receptor 4 (TLR4). Analogues of SP600125 or anthrapyrazolone inhibit
JNK activity.
Figure 2 | Molecular structures of the compounds and codes used. Numbering is given on SP600125 and is followed for analogues.
www.nature.com/scientificreports
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logues were prepared as follows: (a) propyl (SPP1), butyl (SPB1) and
allyl (D8) groups as N-alkyl substitution in anthrapyrazolone to
activate hydrophobic contacts; (b) substitution of hydroxyethyl
group (D1) supposed to activate hydrophilic contacts; (c) D4, D5,
D6, D7 and D9 with alkyl groups and/or halogen atoms substituted
on the periphery of anthrapyrazolone for enhanced hydrophilic con-
tacts at the active site through halogen atoms and (d) D2 andD3with
both hydroxyethyl group and chlorine atoms which may provide
additional hydrophilic interactions. These compounds were charac-
terized by 1H and 13C NMR spectroscopy, ESI-MS and their purity is
further confirmed by mass-directed preparative HPLC (analytical
purity .99%). The analogues were crystallized from different sol-
vents and their X-ray crystal structures were determined (Supple-
mentary Fig. S3, Table S1). The selection of specific analogues of
anthrapyrazolone for biochemical activity has been done as follows.
The first step involves the analysis of docking features of each of the
analogues followed by in vitro cell viability studies to benchmark the
efficiency and specificity as well as cytotoxicity of each compound.
Docking simulations were performed with the coordinates taken
from the PDB (Protein Data Bank) to evaluate the binding features.
In silico studies were thus carried out using all three JNK structures
viz. 1PMV28 (JNK3), 3E7O30 (JNK2) and 2NO331 (JNK1). In addi-
tion, hydrophobic and hydrophilic interactions at the active site of
JNK3 with SP600125 were also determined. The binding energy
values obtained from docking studies which provide confirmatory
evidence in terms of the best analogues of SP600125 (Table S2–S4,
Supplementary Information). The binding energy of JNK3-
SP600125 complex (PDB: 1PMV) is –8.05 Kcal mol21. Molecules
containing hydroxyethyl group with or without chloro group (D1,
D2 and D3) and alkyl 1 chloro groups (D4, D5, D6 and D7) exhib-
ited higher binding energies compared to the parent SP600125. This
shows that substitution of hydroxyethyl/alkyl/chloro group on
anthrapyrazolone should have improved the interactions leading to
higher binding energies. On the other hand, allyl (D8) and trifluoro
substitution in the alkyl chain (D9) did not show any improvement
in the binding energy suggesting that such molecules are not suitable
for stable productive interaction at the active site of JNK. The relative
ranking of binding energies for the compounds is as follows:
D1.D2.D3.D4.D5.D6.D7<SP60015,D8,D9 (Table S2–
S4, Supplementary Information).
Interestingly, in silico studies show that the analogues form both
hydrogen and halogen bonds with active site residues in the binding
site of 2NO3, 3E7O and 1PMV (Supplementary Fig. S4-S6). D1, D2
and D3 form hydrogen bonds with Met149 and Asn152 at the bind-
ing site of JNK3 and also D2 forms a halogen contact with Met149 in
JNK3 active site (1PMV; Table S2, Supplementary Information).
Anthrapyrazolone analogues inhibit JNK in vitro. Cell viability
assays coupled with western blot analysis of 1,9-pyrazoloanthrone
(anthrapyrazolone) suggested that JNK activity is inhibited at
concentration higher that 10 mM in LPS/endotoxin stimulated
macrophages with minimal off-target effects on ERK1/2 and p38
MAPK (Supplementary Fig. S7a & S7b). Accordingly, minimal
inhibitory concentration for 1,9-pyrazoloanthrone exceeded
10 mM in LPS triggered JNK mediated activation of AP1 promoter
activity (Supplementary Fig. S7c). Prior to analysis of the inhibitory
potentials of the analogues of 1,9-pyrazoloanthrone, a preliminary
screen was carried out to examine the level of cytotoxicity on
macrophages. In general, most of the tested analogues/molecules
exhibited significant cytotoxicity (30%–40% decrease in cell
viability) when used at concentrations .30 mM (Supplementary
Fig. S8). This observation leads to the use of compounds at
,30 mM concentration to assess their inhibitory efficacy on JNK
in endotoxin treated macrophages. In addition to monitoring the
specific inhibition of JNK, inhibitory properties of tested molecules
were also evaluated on other MAPKs like ERK1/2 and p38 to assess
their off-target effects (Fig. 3). Interestingly, D1 (2-hydroxyethyl)
and D2 (2-hydroxyethyl-7-chloro) showed a significant selective
inhibitory effect on JNK at concentrations # 1 mM (Fig. 3d–e),
which is 10 fold less as compared to SP600125 (Supplementary
Fig. S7a & S7b) with minimal off-target effects on other MAPKs.
Significantly, SPB1 (N-butyl derivative of 1,9-pyrazoloanthrone)
exhibited potent inhibitory effects on JNK from 1 mM onwards.
However, unlike D1 (2-hydroxyethyl) and D2 (2-hydroxyethyl-7-
chloro), SPB1 demonstrated substantial off-targets effects on
activation of ERK1/2 and p38 in macrophages (Fig. 3b). Similarly,
SPP1 and D9 showed the inhibitory effect on JNK at concentrations
as low as from 5 mM, but exhibited non-specific effects at higher
concentrations (Fig. 3). This could be attributed to the varying
binding energies exhibited by these compounds with that of JNK
as well as for other MAPK’s (Table S2–S4, Supplementary Infor-
mation). It may be noted that compounds containing halogens
(chlorine) may contribute to ligand interaction in forming steady
halogen bonds with biological molecules. For example, D3, D4,
D5, D6 and D7 exhibited potent inhibitory effect on JNK activity
compared to SP600125 (Fig. 3f–k). However, despite their inhibitory
effects at lower concentrations in comparison to SP600125, these
inhibitors also blocked the activation of ERK1/2 and p38 MAPKs
at higher concentrations, suggesting significant off-target effects
(Fig. 3f–k).
Of themolecules screened as summarized inTable 1, we attempted
to elucidate the lowest possible concentration of D1, D2, D7 and D9
required to inhibit JNK activity in vitro as well as in vivo. Minimal
inhibitory concentrations remain at 1 mM for D1 andD2 as analyzed
by phosphorylation of c-Jun (Fig. 4) as well as JNK mediated activa-
tion of AP1 promoter activity (Fig. 4b & 4e) respectively. However,
inhibition of JNK or JNK mediated activation of AP1 promoter
activity required higher concentration of D7 and D9 (Supple-
mentary Fig. S9). Further, at tested concentrations, D1 and D2 sig-
nificantly inhibited the endotoxin-mediated expression of key
immune genes including COX-2, TNF-a, IL-12 and IL-6 in macro-
phages (Fig. 4c & 4f). Interestingly, both D7 and D9 also inhibited
endotoxin stimulated pro-inflammatory genes expressions (Supple-
mentary Fig. S9). Taken together, these in vitro data clearly point
out that D1 (2-hydroxyethyl) and D2 (2-hydroxyethyl-7-chloro) as
potent inhibitors with greater selectivity in comparison to other
inhibitors including commercially available JNK inhibitor SP600125
(anthrapyrazolone).
Inhibitors of JNK block endotoxin triggered inflammation in
vivo. Based on the inhibitory potential of a few selected
molecules like D1, D2, D7 and D9, their efficacy in blocking as
well as resolving endotoxin elicited inflammation in mouse model
of septicemia was analyzed. Mice were intravenously administered
with the selected molecules as described in materials and methods.
Subsequently, mice were challenged intravenously with endotoxin
and were monitored for their survival at regular intervals of 12 h.
As shown, mice injected with endotoxin alone succumbed to
death within 12 to 24 h. However, mice that were administered
with D1 and D2 prior to endotoxin challenge exhibited
significantly higher survival time. Interestingly, survival of mice
that were administered with D7 and D9 prolonged compared to
endotoxin challenged controls, matching the survival efficacy
imparted by SP600125 (Fig. 5). DMSO, which serves as a
vehicle control, did not show significant effects on the survival
of mice throughout the chosen experimental time points (Fig. 5a–
b). We do believe that considerable survival benefits imparted by
D7 and D9 might be due to their off-targets effects on ERK1/2
and p38 MAPKs along with JNK. In all, it should be stressed that
D1 and D2 mediated rescue of mice from endotoxin induced
septic shock was significantly stronger compared to D7, D9 or
SP600125.
www.nature.com/scientificreports
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Endotoxin mediated septicemia often involve excessive inflam-
mation mediated by several inflammatory genes including COX-2,
TNF-a, IL-12 and IL-6. As shown in Fig. 5c–f, D1 and D2 markedly
reduced the endotoxin triggered COX-2, TNF-a, IL-12 and IL-6
expression levels in spleen and lymph nodes of endotoxin challenged
mice which correlates with the survival of mice. Similar results were
obtained with D7 and D9 (Fig. 5) but it should be remembered that
the survivability of mice is shorter as compared to D1 and D2.
Discussion
Endotoxin or LPS induced septic shock, is one of the serious concerns
in ICU of hospitals where inmicroscopic level of contamination with
hospital borne microbes culminates in massive induction of inflam-
mation with augmented expression of several inflammatory mole-
cules. We have screened a library of anthrapyrazolone analogues for
their potential application in the treatment of Inflammation assoc-
iated disorders such as sepsis. It is observed that hydroxyl and hal-
ogen substitutions on the periphery of 1,9-pyrazoloanthrone
enhanced the binding potency towards JNK resulting in its inhibi-
tion. Based on the results from both in vitrowithmacrophages and in
vivowith themousemodel of septicemia, the potential role of D1 and
D2 in regulating endotoxin induced inflammation is firmly estab-
lished. Altogether, the in vitro as well as the in vivo data clearly
potentiates the selective inhibitory capacity of small molecule inhi-
bitors like D1 and D2 which can facilitate the treatment of current
inflammatory disorders when used in combination with the available
drugs having varied efficacies. To our knowledge, this is the first
Figure 3 | Treatment of mouse macrophages with anthrapyrazolone and its analogues reduces activation of MAPkinase along with JNK to a varied
extent. Western blot analysis of pc-Jun in macrophages treated with respective inhibitors at higher concentrations as shown in (a) SPB1, (b) SPP1,
(c) D9, (d) D1 (2-hydroxyethyl), (e) D2, (2-hydroxyethyl-7-chloro), (f) D3, (g) D4, (h) D5, (i) D6, (j) D7, (k) D8 and (l) SP600125 for 1 hour followed by
LPS (100 ng/ml) treatment for additional 1 hour. Representative blots of three independent experiments are shown.
Table 1 | List of inhibitors tested for in vitro analysis of JNK inhibi-
tion at different concentration
Inhibitors Tested p c-Jun p ERK 1/2 p P38
SP600125 .10 uM No effect No effect
SPB1 .5 uM .10 uM .10 uM
SPP1 .10 uM No effect No effect
D1 .1 uM No effect No effect
D2 .1 uM No effect No effect
D3 .5 uM No effect .5 uM
D4 .5 uM .10 uM .10 uM
D5 .20 uM .5 uM No effect
D6 .5 uM .5 uM .20 uM
D7 .1 uM .5 uM .20 uM
D8 .5 uM .5 uM .1 uM
D9 .1 uM No Effect .10 uM
www.nature.com/scientificreports
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description and rigorous biochemical characterization of selective
JNK inhibitors. These inhibitors may facilitate the generation of
novel therapeutics to treat sepsis and also pave the way to understand
the essential biological functions of JNK.
Methods
Chemistry. Analogues of anthrapyrazolone were synthesized based on several
modified procedures as described in the Supplementary Information details and
provided synthetic schemes, procedures and additional characterization of these
molecules.
Isolation of peritoneal macrophages. The experiments with mouse macrophages
were carried out after the approval from the Institutional Ethics Committee for
animal experimentation as well as from Institutional Biosafety Committee. All the
methods were approved by Indian Institute of Science and were carried out in
accordance with the approved guidelines. Mouse peritoneal macrophages isolated
from C57BL/6J were utilized for majority of the experiments in the current study. In
brief, mice were intraperitoneally injected with thioglycollate (2 ml of 2X
concentrate/mice). After 4 days of injection, mice were sacrificed and peritoneal
cavity were flushed with ice cold PBS. Cells were pelleted down (1500 rpm/5 min at
4uC) and resuspended DMEM (Gibco, USA) supplemented with 10% fetal bovine
serum for further experiments.
Plasmids, transfections and inhibitor treatments. The AP1 luciferase construct
used in the current study was assembled as described previously32. RAW264.7
macrophages were transfected with 7XAP1 luciferase construct with
polyethylenimine (Sigma, USA) in serum free and antibiotic free medium. After
8 hours, medium was changed to complete DMEM and left for incubation for
Figure 4 | Anthrapyrazolone and its analogues inhibit JNK activity as well as other MAPkinases in concentration dependent manner in mouse
macrophages. (a, b) Inhibitory effect of D1 (2-hydroxyethyl) over phosphorylation of c-Jun at lower concentrations analyzed by western blot in mouse
macrophages and AP1 luciferase activity (RAW 264.7 macrophages) upon stimulation with LPS for 1 hour and 12 hour respectively. (d, e) Inhibitory
effect of D2 (2-hydroxyethyl-7-chloro) over phosphorylation of c-Jun at lower concentrations analyzed by western blot and AP1 luciferase activity upon
stimulation with LPS for 1 hour and 12 hour respectively. (c, f) Real Time PCR analysis of COX-2, TNF-a, IL-12 and IL-6 in macrophages upon
treatment with D1 and D2 at lower concentrations in presence of LPS (100 ng/ml) respectively. Representative blots of three independent experiments
were shown. n53, SE 6 mean.
www.nature.com/scientificreports
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48 hours. Later, macrophages were treated with LPS (100 ng/ml, Sigma, USA) in the
presence or absence of respective inhibitors at various concentrations for 12 hours
and promoter luciferase activity was analyzed. Small molecule inhibitors used in the
study were added to the cells at respective concentrations 60 minutes prior to the
treatment with LPS and then experiment was carried out for experimental time
points. Inhibitors were retained till the end point of the experiment. All the inhibitors
utilized in the study were dissolved in DMSO (Sigma, USA). 0.1% DMSO served as a
vehicle control and had no effect on the LPS activated signaling intermediates in the
current study.
MTT assay. Mouse macrophages were seeded in 96 well plates (75,000cells/well) in
200 ml of DMEM complete medium and incubated overnight. Later cells were treated
with various small molecule inhibitors reconstituted in DMSO at various
concentrations as mentioned for 12 hours. Post 12 hours treatment, medium was
removed carefully and fresh medium (100 ml/well) was added. 20 ml of MTT (5 mg/
ml) reagent was added to each well and incubated for 4 hours at 37uC aseptically.
Medium was removed and cells were added with DMSO. Absorbance of the solution
was measured at 550 nm using an ELISA reader (Molecular Devices, USA).
Luciferase assays. Luciferase activity was assayed using luciferase assay reagent
(Promega). The results were normalized for transfection efficiencies by assay of b-
galactosidase activity.
Western blotting. Macrophages were treated with respective small molecule
inhibitor as mentioned and then stimulated with LPS (Sigma-Aldrich, USA), 100 ng/
ml, for additional 60 min. Cells were washed twice with PBS, scrapped off the culture
dish and collected by centrifugation. Cell lysates were prepared in RIPA buffer
constituting 50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.25% Sodium deoxycholate,
150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 mg/ml of each aprotinin, leupeptin,
pepstatin, 1 mM Na3VO4, 1 mM NaF and incubated on ice for 30 min. Whole cell
lysates were collected by centrifuging lysed cells at 13,000 g, 10 min at 4uC. Equal
amount of protein from each cell lysate was subjected to SDS-PAGE and transferred
onto PVDF membranes (Millipore, USA) by semidry western blotting (Bio-Rad,
USA) method. Nonspecific binding was blocked with 5% nonfat dry milk powder in
TBST (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, and 0.1% Tween 20) for 60 min.
The blots were probed with anti phospho Ser 63 c-Jun or anti-Thr180/Tyr182
phospho p38 MAPK, anti-Thr202/Tyr204 phospho ERK1/2, (Cell Signaling
Technology, USA) for 12 hours at 4uC and thenwashedwith TBST thrice followed by
anti-rabbit IgG HRP conjugated secondary antibody (Jackson Immuno Research,
USA) for 2 hours at 4uC. Blots were washed and developed using enhanced
chemiluminescence detection system (Perkin Elmer, USA) as per manufacturer’s
instructions. Blots were probed with anti-b-actin HRP (Sigma-Aldrich, USA) to
ensure equal loading of protein.
Real Time PCR.Macrophages were treated with respective small molecule inhibitors
followed by treatment with LPS (100 ng/ml) for 12 hours. Total cellular RNA from
macrophages was isolated by TRI reagent (Sigma-Aldrich, USA). 1 mg of total RNA
was converted into cDNA using First strand cDNA synthesis kit (Bioline, UK).
Quantitative real time RT-PCR was performed using SYBR Green PCR mixture
Figure 5 | Anthrapyrazolone analogues block LPS induced inflammation in vivo. (a) LPS induced inflammation is inhibited by intravenous
administration of the inhibitors as mentioned in materials and methods. Viability of mice is monitored at regular time intervals (no. of mice per each
group 5 6). (b) Bar graph representation of % mice survival data as given in (a). (c, d, e & f) Real Time PCR analysis of COX-2, TNF-a, IL-12 & IL-6
respectively in lymph nodes and spleen of mice injected with small molecule inhibitors. Representative blots of three independent experiments were
shown. n53, SE 6 mean.
www.nature.com/scientificreports
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(KAPA Biosystems, USA) for quantification of the target gene expression. All the
experiments were repeated at least three times independently to ensure the
reproducibility of the results. In case of in vivo challenge studies, total RNA was
isolated from the tissues and cDNAwas synthesized as mentioned above and used for
RT-PCR analysis of various target genes. The primers used for quantitative RT-PCR
amplification are as follows: COX-2 FP: 59- gtatcagaaccgcattgcctc-39, COX-2 RP: 59-
cggcttccagtattgaggagaacagat-39; TNF-a FP: 59-agcccacgtcgtagcaaaccaccaa-39, TNF-a
RP: 59-acacccattcccttcacagagcaat-399; Il-12 FP: 59-gaagttcaacatcaagagcagtag-39, IL-12
RP: 59-agggagaagtaggaatgggg-39; IL-6 FP: 59- aaagagttgtgcaatggcaattct-39, IL-6 RP:
59-aagtgcatcatcgttgttcataca-39. GAPDH FP: 59-gagccaaacgggtcatcatct-39, GAPDH
RP: 59-gaggggccatccacagtctt-39.
In vivo challenge of mice. In each group 6 mice (C57BL/6J) were used to assess the
effect of small molecules in LPS induced inflammation. Mice were intravenously
injected with 100 mg of respective small molecule inhibitors. After 6 hours of
injection, mice were intravenously challenged with LPS (10 ug/mice) to induce
inflammation andweremonitored for survival. Spleen and lymph nodes were isolated
and utilized for RT-PCR analysis of COX-2, TNF-a, IL-6 and IL-12. Equal volumes of
DMSO, vehicle control showed no significant effect on the mice survival.
Statistical analysis. Levels of significance for comparison between samples were
determined by the Student t test distribution and one-way ANOVA. The data in the
graphs are expressed as the mean 6 SE and p values , 0.05 were defined as
significant. Graphpad Prism 5.0 software (Graphpad software, USA) was used for all
the statistical analysis.
1. Martin, G. S., Mannino, D.M., Eaton, S. &Moss,M. The epidemiology of sepsis in
the United States from 1979 through 2000. N Engl J Med. 348, 1546–1554 (2003).
2. Angus, D. C. et al. Epidemiology of severe sepsis in the United States: analysis of
incidence, outcome, and associated costs of care. Crit Care Med. 29, 1303–1310
(2001).
3. Vincent, J. L. et al. Sepsis in European intensive care units: results of the SOAP
study. Crit Care Med. 34, 344–353 (2006).
4. Dellinger, R. P. et al. Surviving Sepsis Campaign: International Guidelines for
Management of Severe Sepsis and Septic Shock, 2012. Intensive Care Med. 39,
165–228 (2013).
5. Angus, D. C. & Poll, T. Severe Sepsis and Septic Shock.NEngl JMed. 369, 840–851
(2013).
6. Macdonald, J., Galley, H. F. &Webster, N. R. Oxidative stress and gene expression
in sepsis. Br. J. Anaesth. 90, 221–232 (2003).
7. White, M. et al. Post-operative infection and sepsis in humans is associated with
deficient gene expression of cc cytokines and their apoptosismediators.Crit. Care.
15, R158 (2011).
8. Riedemann, N. C., Ren-Feng, G. & Peter, A.W. The enigma of sepsis. J Clin Invest.
112, 460–467 (2003).
9. Annane, D., Bellissant, E. & Cavaillon, J. M. Septic shock. Lancet 365, 63–78
(2005).
10. Ki, Y. W., Park, J. H., Lee, J. E., Shin, I. C. & Koh, H. C. JNK and p38 MAPK
regulate oxidative stress and the inflammatory response in chlorpyrifos-induced
apoptosis. Toxicology Letters. 218, 235–245 (2013).
11. Karin, M. The Regulation of AP-1 Activity by Mitogen-activated Protein Kinases.
J Biol Chem. 270, 16483–16486 (1995).
12. Ip, Y. T. &Davis, R. J. Signal transduction by the c-JunN-terminal kinase (JNK)—
from inflammation to development. Curr. Opin. Cell Biol. 10, 205–219 (1998).
13. Newton, K. & Dixit, V. M. Signaling in Innate Immunity and Inflammation. Cold
Spring Harb Perspect Biol. 4, a006049 (2012).
14. Kallunki, T. et al. JNK2 contains a specificity-determining region responsible for
efficient c-Jun binding and phosphorylation. Genes & Dev., 8, 2996–3007 (1994).
15. Foletta, V. C., Segal, D. H. & Cohen, D. R. Transcriptional regulation in the
immune system: all roads lead to AP-1. J Leukoc Biol. 63, 139–152 (1998).
16. Jain, J., Archer, V. E. V. & Rao, A. Analysis of the AP-1 sites in the IL-2 promoter.
J Immunol. 148, 1240–1250 (1992).
17. Ameyar, M., Wisniewska, M. &Weitzman, J. B. A role for AP-1 in apoptosis: the
case for and against. Biochimie. 85, 747–752 (2003).
18. Warren, H. S. Editorial: Mouse models to study sepsis syndrome in humans.
Journal of leukocyte biology. 86, 199–201 (2009).
19. Bode, A. M. & Dong, Z. The functional contrariety of JNK. Mol. Carcinog. 46,
591–598 (2007).
20. Kyriakis, J. M. et al. R. J. The stress-activated protein kinase subfamily of c-Jun
kinases. Nature 369, 156–160 (1994).
21. Bennett, B. L. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal
kinase. Proc Natl Acad Sci. 98, 13681–13686 (2001).
22. De Oliveira, E. A. G. et al. Structural and Functional Characterization of the
Protein Kinase Mps1 in Arabidopsis thaliana. PloS one. 7, e45707 (2012).
23. Schmidt, M., Budirahardja, Y., Klompmaker, R. &Medema, R. H. Ablation of the
spindle assembly checkpoint by a compound targeting Mps1. EMBO reports. 6,
866–872 (2005).
24. Chu, M. L., Chavas, L. M., Douglas, K. T., Eyers, P. A. & Tabernero, L. Crystal
Structure of the Catalytic Domain of the Mitotic Checkpoint Kinase Mps1 in
Complex with SP600125. J. Biol. Chem. 283, 21495–21500 (2008).
25. Maroney, A. C. et al. CEP-1347 (KT7515), an inhibitor of JNK activation, rescues
sympathetic neurons and neuronally differentiated PC12 cells from death evoked
by three distinct insults. J. Neurochem. 73, 1901–1912 (1999).
26. Bain, J., Mclauchlan, H., Elliott, M. & Cohen, P. The specificities of protein kinase
inhibitors: an update. Biochem. J. 371, 199–204 (2003).
27. Karothu, D. P., Venkataramaiah, N. & Row, T. N. G. 1, 9-pyrazoloanthrone as a
Colorimetric and turn-on Fluorometric chemosensor: Structural implications.
Cryst. Growth Des. 14, 2118–2122 (2014).
28. Scapin, G., Patel, S. B., Lisnock, J., Becker, J. W. & LoGrasso, P. V. The structure of
JNK3 in complex with small molecule inhibitors: structural basis for potency and
selectivity. Chem. Biol. 10, 705–712 (2003).
29. Karothu, D. P. et al. Alkyl chain substituted 1, 9-pyrazoloanthrones exhibit
prominent inhibitory effect on c-Jun N-terminal kinase (JNK). Org. Biomol.
Chem. 12, 4656–4662 (2014).
30. Shaw, D. et al. The crystal structure of JNK2 reveals conformational flexibility in
the MAP kinase insert and indicates its involvement in the regulation of catalytic
activity. J. Mol. Biol. 383, 885–893 (2008).
31. Liu, M. et al. Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-
terminal kinase inhibitors: Synthesis and SAR studies. Bioorg. Med. Chem. Lett.
17, 668–672 (2007).
32. Aguiari, G. et al. Polycystin-1 regulates amphiregulin expression through CREB
and AP1 signalling: implications in ADPKD cell proliferation. J. Mol. Med. 90,
1267–1282 (2012).
Acknowledgments
We thank the Central Animal facility, Indian Institute of Science (IISc) for providing mice
for experimentation. We sincerely thank Dr. Gianluca Aguiari, Universita degli studi di
Ferrara, Italy for 7XAP1 luciferase construct. This study is supported by funds from the
Department of Biotechnology (DBT), Department of Science and Technology (DST),
Council for Scientific and Industrial Research (CSIR) and Indian Council of Medical
Research (ICMR), Government of India and the Indo- French Center for Promotion of
Advanced Research (CEFIPRA) (Reference number 4803-1). Infrastructure support from
ICMR (Center for advanced study in Molecular Medicine), DST (FIST) and UGC (special
assistance) (KNB); fellowship from CSIR (JT and KDP) are acknowledged. Authors thank
Dr. S Cherukuvada for useful discussions. TNG thanks DST for JC Bose fellowship.
Author contributions
The project was conceived by K.N.B. and T.N.G. Project executed by J.T. and K.D.P. Both
K.S. and A.B. contributed to the insilico studies. K.D.P. carried out the synthesis and
structural characterization of compound library. J.T. performed biological experiments.
K.D.P., J.T., K.N.B. and T.N.G. wrote the manuscript, and all authors discussed the results
and commented on the manuscript. J.T. and K.D.P. contributed equally as first authors (#).
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Prasad, K.D. et al. Anthrapyrazolone analogues intercept
inflammatory JNK signals to moderate endotoxin induced septic shock. Sci. Rep. 4, 7214;
DOI:10.1038/srep07214 (2014).
This work is licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are included in the
article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need
to obtain permission from the license holder in order to reproduce thematerial. To
view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7214 | DOI: 10.1038/srep07214 7
